112 related articles for article (PubMed ID: 1623479)
21. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
Yoshida K; Jastaniyah N; Sturdza A; Lindegaard J; Segedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz I; Haie-Meder C; Sasaki R; Pötter R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):788-96. PubMed ID: 26530747
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
23. Pelvic and parametrial lymph nodes in the quality control of the surgical treatment of cervical cancer.
Girardi F; Pickel H; Winter R
Gynecol Oncol; 1993 Sep; 50(3):330-3. PubMed ID: 8406196
[TBL] [Abstract][Full Text] [Related]
24. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB.
Minig L; Colombo N; Zanagnolo V; Landoni F; Bocciolone L; Cárdenas-Rebollo JM; Iodice S; Maggioni A
Int J Gynecol Cancer; 2013 Nov; 23(9):1647-54. PubMed ID: 24100590
[TBL] [Abstract][Full Text] [Related]
25. Preoperatively Assessable Clinical and Pathological Risk Factors for Parametrial Involvement in Surgically Treated FIGO Stage IB-IIA Cervical Cancer.
Canaz E; Ozyurek ES; Erdem B; Aldikactioglu Talmac M; Yildiz Ozaydin I; Akbayir O; Numanoglu C; Ulker V
Int J Gynecol Cancer; 2017 Oct; 27(8):1722-1728. PubMed ID: 28617687
[TBL] [Abstract][Full Text] [Related]
26. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
27. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery.
Bean LM; Ward KK; Plaxe SC; McHale MT
Am J Obstet Gynecol; 2017 Sep; 217(3):332.e1-332.e6. PubMed ID: 28522318
[TBL] [Abstract][Full Text] [Related]
28. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer?
Togami S; Kamio M; Yanazume S; Yoshinaga M; Douchi T
Int J Gynecol Cancer; 2014 Jul; 24(6):1072-6. PubMed ID: 24905616
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma.
Werner-Wasik M; Schmid CH; Bornstein L; Ball HG; Smith DM; Madoc-Jones H
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1309-17. PubMed ID: 7635770
[TBL] [Abstract][Full Text] [Related]
30. [Radical hysterectomy with pelvic lymphadenectomy in patients with carcinoma of the uterine cervix--3 years' experience].
Bosković V; Glisić A; Petković S
Srp Arh Celok Lek; 1998; 126(5-6):183-7. PubMed ID: 9863378
[TBL] [Abstract][Full Text] [Related]
31. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer?
Marnitz S; Köhler C; Roth C; Füller J; Hinkelbein W; Schneider A
Gynecol Oncol; 2005 Dec; 99(3):536-44. PubMed ID: 16126259
[TBL] [Abstract][Full Text] [Related]
32. Parametrial spread of cervical cancer in patients with negative pelvic lymph nodes.
Winter R; Haas J; Reich O; Koemetter R; Tamussino K; Lahousen M; Petru E; Pickel H
Gynecol Oncol; 2002 Feb; 84(2):252-7. PubMed ID: 11812083
[TBL] [Abstract][Full Text] [Related]
33. Comparison of laparoscopic versus abdominal radical hysterectomy for FIGO stage IB and IIA cervical cancer with tumor diameter of 3 cm or greater.
Kong TW; Chang SJ; Lee J; Paek J; Ryu HS
Int J Gynecol Cancer; 2014 Feb; 24(2):280-8. PubMed ID: 24407571
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy.
Xia X; Xu H; Wang Z; Liu R; Hu T; Li S
Am J Clin Oncol; 2016 Dec; 39(6):604-608. PubMed ID: 24937635
[TBL] [Abstract][Full Text] [Related]
35. [Wertheim-operation: 5-year survival of 501 consecutive patients with cervical cancer].
Papp Z; Csapó Z; Mayer A; Hupuczi P
Orv Hetil; 2006 Mar; 147(12):537-45. PubMed ID: 16696377
[TBL] [Abstract][Full Text] [Related]
36. Indication and efficacy of radiation therapy following radical surgery in patients with stage IB to IIB cervical cancer.
Okada M; Kigawa J; Minagawa Y; Kanamori Y; Shimada M; Takahashi M; Oishi T; Terakawa N
Gynecol Oncol; 1998 Jul; 70(1):61-4. PubMed ID: 9698475
[TBL] [Abstract][Full Text] [Related]
37. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML
Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837
[TBL] [Abstract][Full Text] [Related]
38. Can parametrectomy be avoided in early cervical cancer? An algorithm for the identification of patients at low risk for parametrial involvement.
Gemer O; Eitan R; Gdalevich M; Mamanov A; Piura B; Rabinovich A; Levavi H; Saar-Ryss B; Halperin R; Finci S; Beller U; Bruchim I; Levy T; Ben Shachar I; Ben Arie A; Lavie O
Eur J Surg Oncol; 2013 Jan; 39(1):76-80. PubMed ID: 23131429
[TBL] [Abstract][Full Text] [Related]
39. Long-term Outcomes of MRI Stage IIB Cervical Cancer.
Yoon A; Park JJ; Park BK; Lee YY; Paik ES; Choi CH; Kim TJ; Kim CK; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2016 Sep; 26(7):1252-7. PubMed ID: 27284726
[TBL] [Abstract][Full Text] [Related]
40. Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.
Höckel M; Horn LC; Manthey N; Braumann UD; Wolf U; Teichmann G; Frauenschläger K; Dornhöfer N; Einenkel J
Lancet Oncol; 2009 Jul; 10(7):683-92. PubMed ID: 19482513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
